Literature DB >> 11280674

Chronic obstructive pulmonary disease patients with invasive pulmonary aspergillosis: benefits of intensive care?

P A Bulpa1, A M Dive, M G Garrino, M A Delos, M R Gonzalez, P A Evrard, Y Glupczynski, E J Installé.   

Abstract

OBJECTIVES: Invasive pulmonary aspergillosis (IPA) is increasingly recognized as a cause of acute respiratory failure in patients with chronic obstructive pulmonary disease (COPD) treated with corticosteroids. For these patients admission in intensive care unit (ICU) is often required for life-support and mechanical ventilation. Whether this approach improves outcome is unknown. DESIGN AND
SETTING: Retrospective study in a university hospital intensive care unit. PATIENTS: Between November 1993 and December 1997, 23 COPD patients were admitted in our ICU and received antifungal agents for possible IPA.
INTERVENTIONS: None. MEASUREMENTS AND
RESULTS: The clinical features and the outcome were reviewed. Diagnosis of IPA was classified as confirmed (positive lung tissue biopsy and/or autopsy) or probable (repeated isolation of Aspergillus from the airways with consistent clinical and radiological findings). Among the 23 patients treated for Aspergillus, 16 fulfilling these criteria for IPA were studied. Steroids had been administered at home to all patients but one and were increased during hospitalization in all. Twelve patients suffered a worsening of their bronchospasm precipitating acute respiratory failure. During ICU stay all patients required mechanical ventilation for acute respiratory failure. Although amphotericin B deoxycholate was started when IPA was suspected (0.5-1.5 mg/kg per day), all patients died in septic shock (n = 5) or in multiple-organ failure.
CONCLUSIONS: The poor prognosis of intubated COPD patients with IPA, in spite of antifungal treatment suggests that further studies are required to define the limits and indications for ICU management of these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11280674     DOI: 10.1007/s001340000768

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  24 in total

1.  Host biomarkers of invasive pulmonary aspergillosis to monitor therapeutic response.

Authors:  Mila Krel; Vidmantas Petraitis; Ruta Petraitiene; Mohit Raja Jain; Yanan Zhao; Hong Li; Thomas J Walsh; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  Combination antifungal treatment of pseudomembranous tracheobronchial invasive aspergillosis: a case report.

Authors:  Francesco G De Rosa; Pierpaolo Terragni; Daniela Pasero; Anna C Trompeo; Rosario Urbino; Anna Barbui; Giovanni Di Perri; V Marco Ranieri
Journal:  Intensive Care Med       Date:  2009-06-16       Impact factor: 17.440

Review 3.  Respiratory Mycoses in COPD and Bronchiectasis.

Authors:  Pei Yee Tiew; Micheál Mac Aogáin; Soo Kai Ter; Stefano Aliberti; James D Chalmers; Sanjay H Chotirmall
Journal:  Mycopathologia       Date:  2021-03-11       Impact factor: 2.574

4.  Invasive pulmonary aspergillosis in acute exacerbation of chronic obstructive pulmonary disease and the diagnostic value of combined serological tests.

Authors:  Xiaofang Gao; Liangan Chen; Guangrong Hu; Haiyu Mei
Journal:  Ann Saudi Med       Date:  2010 May-Jun       Impact factor: 1.526

5.  Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria.

Authors:  R C Barton; R P Hobson; H McLoughlin; A Morris; B Datta
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-01       Impact factor: 3.267

6.  Th2 allergic immune response to inhaled fungal antigens is modulated by TLR-4-independent bacterial products.

Authors:  Jenna B Allard; Lisa Rinaldi; Matthew J Wargo; Gilman Allen; Shizuo Akira; Satoshi Uematsu; Matthew E Poynter; Deborah A Hogan; Mercedes Rincon; Laurie A Whittaker
Journal:  Eur J Immunol       Date:  2009-03       Impact factor: 5.532

7.  Successful pneumonectomy for invasive pulmonary aspergillosis and advanced non-small cell-lung cancer.

Authors:  Shohei Minesaki; Nobuyuki Koyama; Hironori Ishida; Kunihiko Kobayashi
Journal:  BMJ Case Rep       Date:  2013-03-14

8.  Clinical features of invasive bronchial-pulmonary aspergillosis in critically ill patients with chronic obstructive respiratory diseases: a prospective study.

Authors:  Hangyong He; Lin Ding; Fang Li; Qingyuan Zhan
Journal:  Crit Care       Date:  2011-01-06       Impact factor: 9.097

9.  Immunoproteomics based identification of thioredoxin reductase GliT and novel Aspergillus fumigatus antigens for serologic diagnosis of invasive aspergillosis.

Authors:  Li-ning Shi; Fang-qiu Li; Mei Huang; Jing-fen Lu; Xiao-xiang Kong; Shi-qin Wang; Hai-feng Shao
Journal:  BMC Microbiol       Date:  2012-01-18       Impact factor: 3.605

10.  Invasive Aspergillus infections in hospitalized patients with chronic lung disease.

Authors:  Mireya Wessolossky; Verna L Welch; Ajanta Sen; Tara M Babu; David R Luke
Journal:  Infect Drug Resist       Date:  2013-05-27       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.